FDA Dec Quarterly: FDA lodgement via our manufacturing partner Andon, is expected shortly in the current quarter.
OTCQX Listing:A successful application requires certain criteria to be met. It is expected that this and other criteria will be met in the month or so after the EGM 16 February 2022.
Both timelines are somewhat rubbery allowing for stretch.
Notwithstanding, given that both are now outside guidance you would think we can expect updates...shortly in a few days or so.
Downdraft volume is light, but in this market uncertainty, real or perceived, needs to be laid to rest.
34.5 cents is the post-consolidation low. Absent any update, that needs to hold.
Add to My Watchlist
What is My Watchlist?
